Mgenplus Co. Ltd. - Asset Resilience Ratio
Mgenplus Co. Ltd. (032790) has an Asset Resilience Ratio of 6.11% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 032790 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2025)
This chart shows how Mgenplus Co. Ltd.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Mgenplus Co. Ltd. asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down Mgenplus Co. Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore long-term investment intensity of Mgenplus Co. Ltd. to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩3.05 Billion | 6.11% |
| Total Liquid Assets | ₩3.05 Billion | 6.11% |
Asset Resilience Insights
- Limited Liquidity: Mgenplus Co. Ltd. maintains only 6.11% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Mgenplus Co. Ltd. Industry Peers by Asset Resilience Ratio
Compare Mgenplus Co. Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 1.69% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
Annual Asset Resilience Ratio for Mgenplus Co. Ltd. (2006–2025)
The table below shows the annual Asset Resilience Ratio data for Mgenplus Co. Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 6.02% | ₩3.60 Billion ≈ $2.44 Million |
₩59.85 Billion ≈ $40.56 Million |
+1.69pp |
| 2024-12-31 | 4.33% | ₩3.09 Billion ≈ $2.09 Million |
₩71.42 Billion ≈ $48.40 Million |
+4.20pp |
| 2023-12-31 | 0.13% | ₩88.82 Million ≈ $60.19K |
₩67.29 Billion ≈ $45.60 Million |
-14.44pp |
| 2022-12-31 | 14.57% | ₩11.07 Billion ≈ $7.50 Million |
₩75.96 Billion ≈ $51.48 Million |
+12.51pp |
| 2018-12-31 | 2.06% | ₩1.08 Billion ≈ $728.64K |
₩52.08 Billion ≈ $35.29 Million |
-2.99pp |
| 2017-12-31 | 5.05% | ₩1.82 Billion ≈ $1.23 Million |
₩35.99 Billion ≈ $24.39 Million |
-0.05pp |
| 2016-12-31 | 5.10% | ₩1.50 Billion ≈ $1.02 Million |
₩29.43 Billion ≈ $19.95 Million |
-1.05pp |
| 2015-12-31 | 6.15% | ₩1.68 Billion ≈ $1.14 Million |
₩27.26 Billion ≈ $18.47 Million |
-15.65pp |
| 2014-12-31 | 21.80% | ₩7.01 Billion ≈ $4.75 Million |
₩32.14 Billion ≈ $21.78 Million |
+5.74pp |
| 2013-12-31 | 16.06% | ₩6.60 Billion ≈ $4.47 Million |
₩41.10 Billion ≈ $27.85 Million |
+2.57pp |
| 2012-12-31 | 13.49% | ₩6.71 Billion ≈ $4.55 Million |
₩49.76 Billion ≈ $33.72 Million |
+3.38pp |
| 2011-12-31 | 10.11% | ₩4.79 Billion ≈ $3.25 Million |
₩47.37 Billion ≈ $32.11 Million |
+3.08pp |
| 2008-12-31 | 7.03% | ₩3.17 Billion ≈ $2.15 Million |
₩45.14 Billion ≈ $30.59 Million |
-12.80pp |
| 2007-12-31 | 19.83% | ₩8.48 Billion ≈ $5.74 Million |
₩42.74 Billion ≈ $28.97 Million |
+9.62pp |
| 2006-12-31 | 10.20% | ₩4.53 Billion ≈ $3.07 Million |
₩44.44 Billion ≈ $30.12 Million |
-- |
About Mgenplus Co. Ltd.
Mgen Solutions Co., Ltd. engages in broadband communication network construction business. The company offers electricity, bio business and fire facility construction business, firefighting equipment and construction; printer developer; manufacturing and supply of electrical and electronic products such as transformers and inductors; artificial intelligence video analysis solution; printer develo… Read more